Morgan Stanley: Enhanced Market Recognition of Biotech Stocks Drives Outperformance, Bullish on AKESO (09926) and Others

Stock News

Sep 23

Morgan Stanley released a research report stating that the total market capitalization of Chinese biotech stocks listed in Hong Kong has surged 154% year-to-date, significantly outpacing the Hang Seng Index's 34% gain over the same period. This performance reflects a major shift in market recognition of domestic pharmaceutical companies' innovation capabilities.

The investment bank expects that accelerated Federal Reserve rate cuts will drive risk appetite adjustments, channeling funds toward growth sectors such as Chinese biotechnology. However, Morgan Stanley anticipates that individual stock performance will continue to depend on company fundamentals, including commercialization execution capabilities and innovation R&D progress.

The firm favors companies with near-term catalysts, including AKESO (09926), INNOCARE (09969), ABBISKO-B (02256), INNOVENT BIO (01801), and DUALITYBIO-B (09606). Additionally, Morgan Stanley has assigned "Outperform" ratings to VISEN PHARMA-B (02561) and Zai Lab (09688).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1177779820"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1177779820\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1177779820?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-23 10:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177779820","market":"sg","top_or_hot":-1,"title":"Morgan Stanley: Enhanced Market Recognition of Biotech Stocks Drives Outperformance, Bullish on AKESO (09926) and Others","media":"Stock News","content":"<p>Morgan Stanley released a research report stating that the total market capitalization of Chinese biotech stocks listed in Hong Kong has surged 154% year-to-date, significantly outpacing the Hang Seng Index's 34% gain over the same period. This performance reflects a major shift in market recognition of domestic pharmaceutical companies' innovation capabilities.</p>\n<p>The investment bank expects that accelerated Federal Reserve rate cuts will drive risk appetite adjustments, channeling funds toward growth sectors such as Chinese biotechnology. However, Morgan Stanley anticipates that individual stock performance will continue to depend on company fundamentals, including commercialization execution capabilities and innovation R&D progress.</p>\n<p>The firm favors companies with near-term catalysts, including AKESO (09926), INNOCARE (09969), ABBISKO-B (02256), INNOVENT BIO (01801), and DUALITYBIO-B (09606). Additionally, Morgan Stanley has assigned \"Outperform\" ratings to VISEN PHARMA-B (02561) and Zai Lab (09688).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Morgan Stanley: Enhanced Market Recognition of Biotech Stocks Drives Outperformance, Bullish on AKESO (09926) and Others</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMorgan Stanley: Enhanced Market Recognition of Biotech Stocks Drives Outperformance, Bullish on AKESO (09926) and Others\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-23 10:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Morgan Stanley released a research report stating that the total market capitalization of Chinese biotech stocks listed in Hong Kong has surged 154% year-to-date, significantly outpacing the Hang Seng Index's 34% gain over the same period. This performance reflects a major shift in market recognition of domestic pharmaceutical companies' innovation capabilities.</p>\n<p>The investment bank expects that accelerated Federal Reserve rate cuts will drive risk appetite adjustments, channeling funds toward growth sectors such as Chinese biotechnology. However, Morgan Stanley anticipates that individual stock performance will continue to depend on company fundamentals, including commercialization execution capabilities and innovation R&D progress.</p>\n<p>The firm favors companies with near-term catalysts, including AKESO (09926), INNOCARE (09969), ABBISKO-B (02256), INNOVENT BIO (01801), and DUALITYBIO-B (09606). Additionally, Morgan Stanley has assigned \"Outperform\" ratings to VISEN PHARMA-B (02561) and Zai Lab (09688).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0502904849.HKD","symbol_name":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","start_time":0,"source_url":"","article_id":"1177779820","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177779820","pubTimestamp":1758593057,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Morgan Stanley released a research report stating that the total market capitalization of Chinese biotech stocks listed in Hong Kong has surged 154% year-to-date, significantly outpacing the Hang...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159837":"生物科技","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","09969":"诺诚健华","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","BK1589":"北水核心资产","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","02256":"和誉-B","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","01801":"信达生物","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","09606":"映恩生物-B","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","BK1161":"生物科技","LU1720050803.USD":"安联全方位中国股票基金","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","09926":"康方生物","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","BK1574":"生物医药B类股","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","BK1583":"高瓴概念","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","02561":"维升药业-B"},"translate_title":"大摩：市场对生物科技股认可度提升推动跑赢表现看好康方生物(09926)等","themeId":"079ddef7faa176ef1b029e2be2a3b56e","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159837":1,"01801":1,"02256":1,"02561":1,"09606":1,"09926":1,"09969":1},"content_text":"Morgan Stanley released a research report stating that the total market capitalization of Chinese biotech stocks listed in Hong Kong has surged 154% year-to-date, significantly outpacing the Hang Seng Index's 34% gain over the same period. This performance reflects a major shift in market recognition of domestic pharmaceutical companies' innovation capabilities.\nThe investment bank expects that accelerated Federal Reserve rate cuts will drive risk appetite adjustments, channeling funds toward growth sectors such as Chinese biotechnology. However, Morgan Stanley anticipates that individual stock performance will continue to depend on company fundamentals, including commercialization execution capabilities and innovation R&D progress.\nThe firm favors companies with near-term catalysts, including AKESO (09926), INNOCARE (09969), ABBISKO-B (02256), INNOVENT BIO (01801), and DUALITYBIO-B (09606). Additionally, Morgan Stanley has assigned \"Outperform\" ratings to VISEN PHARMA-B (02561) and Zai Lab (09688).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}